Actionable news
All posts from Actionable news
Actionable news in PTX: Pernix Therapeutics Holdings, Inc.,

On November

Inter Partes

Review of US Patent No. 7,332,183 (the 183 patent). The 183 patent is owned by POZEN Inc. and licensed by Pernix and is one of the several FDA Orange Book listed patents covering Treximet (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura.

The validity of the 183 patent has previously been upheld on all counts by the United States Court of Appeals for the Federal Circuit.In 2012, the Federal Circuit upheld the District Courts decision on validity of the 183 patent against challenges by three generic companies. The 183 patent broadly claims a bi-layer pharmaceutical tablet having a triptan and an NSAID (nonsteroidal anti-inflammatory drug) in separate layers that release independently of each other. This patent expires April 2026, including six months pediatric exclusivity.

Inter Partes

Review is a trial proceeding conducted with the USPTO Patent...